ADICET Bio, Inc. expected to post a loss of $1.59 a share - Earnings Preview

What happened

ADICET Bio, Inc. is expected to report no change in quarterly revenue on November 3 for the period ending September 30, 2026, with analysts forecasting a loss of $1.59 per share, according to LSEG's mean estimate.

Confirmed

Global impact / market context

A forecast loss of $1.59 a share means analysts expect the company to spend more than it earns, which for a small drug developer can mean relying on cash reserves or raising new money to fund research.

Analyst inference

All six analysts covering the stock rate it a buy or strong buy, and the $24.00 median price target sits far above the $3.58 last close, suggesting the shares have fallen well below analyst expectations.

Analyst inference

What to watch

1. Watch the November 3 report to see whether actual revenue matches the forecast of no change from the prior-year quarter, since any shortfall would undercut the current analyst view. Confirmed
2. Watch for company plans to raise cash or cut spending, because ongoing per-share losses of this size may require new funding that could dilute existing shareholders. Proposed
3. Watch whether the actual loss per share comes in better or worse than $1.59, since past results beat estimates in six of eight quarters but missed on two other occasions. Analyst inference

Evidence

• Original source link unavailable